Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
ELUCIREM should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of ELUCIREM (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of ELUCIREM (gadopiclenol) at a dose of 05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that ELUCIREM (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
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
Vec6LgVFaSkz7g01
